CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 35,032 enrolled
Drug / intervention
Adherent with 5-alpha-reductase inhibitor (5ARI) therapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01334723
NCT01334723N/ACompleted
CompareCT.gov

Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia

GlaxoSmithKline·observational·Posted Apr 13, 2011·Updated May 30, 2017

In Brief

An observational study evaluating Adherent with 5-alpha-reductase inhibitor (5ARI) therapy and Non-adherent to 5ARI therapy for Prostatic Hyperplasia. Completed, enrolled 35,032 participants.

Detailed Summary

This retrospective study aims to quantify the relationship between 5-alpha-reductase inhibitor (5ARI) adherence / length of therapy and the likelihood of acute urinary retention (AUR) or prostate surgery in patients with benign prostatic hyperplasia (BPH) as well as the economic impact associated with these medical encounters. The Integrated Health Care Information Solutions (IHCIS) database will be utilized for this study (2000-2006).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Hyperplasia
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 13, 2011
Enrollment StartApr 1, 2010
Primary CompletionApr 1, 2010
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 15.2 years ago

Interventions

Adherent with 5-alpha-reductase inhibitor (5ARI) therapydrug

Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)

Non-adherent to 5ARI therapydrug

Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)